Promising Uses of Calcium‐Channel Blocking Agents

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Volumn 4, Issue 3, 1984, Pages 137-143

  Bussey, Henry I ^a,b   Talbert, Robert L ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADRENALIN; ANGIOTENSIN; CALCIUM CHANNEL BLOCKING AGENT; CAPOTENE; CAPTOPRIL; CLONIDINE; CROMOGLYCATE DISODIUM; DIHYDROERGOCRYPTINE; DILTIAZEM; GLUCAGON; GLYCERYL TRINITRATE; HISTAMINE; HYDRALAZINE; ISOSORBIDE DINITRATE; METHACHOLINE; NIFEDIPINE; NORADRENALIN; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PLACEBO; UNCLASSIFIED DRUG; VERAPAMIL; YOHIMBINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DRUG THERAPY; ENDOCRINE GLAND; GREAT BLOOD VESSEL; HEART; HEART DISEASE; HUMAN; LUNG; MIGRAINE; ONCOLOGY; PERIPHERAL VASCULAR SYSTEM; RAYNAUD PHENOMENON; RESPIRATORY SYSTEM; SHORT SURVEY; THERAPY;

EID: 0021261151     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/j.1875-9114.1984.tb03339.x     Document Type: Article

References (77)

1. Calcium‐channel blocking agents
2. Mechanism of action of calcium‐channel blocking agents
3. The calcium antagonist, mechanism of action and pharmacologic effects
4. Calcium blockers. I
5. Calcium blockers. II
6. Verapamil therapy for stable and unstable angina pectoris: calcium channel antagonists in perspective
7. Introduction
8. The use of diltiazem hydrochloride in cardiovascular disorders
9. Update on calcium‐channel blocking agents
10. Treatment of severe hypertension and hypertensive emergency with nifedipine, a calcium antagonistic agent
11. Nifedipine in hypertensive emergencies
12. Ischemic ECG changes with initial nifedipine therapy of severe hypertension (letter)
13. Primary pulmonary hypertension: effects of nifedipine (letter)
14. Failure of nifedipine treatment in primary pulmonary hypertension
15. Nifedipine inhibits hypoxic pulmonary vasoconstriction in stable patients with COPD (abstract)
16. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine
17. Nifedipine in secondary pulmonary hypertension, (abstract)
18. Pulmonary hypertension: comparative effects of nifedipine versus hydralazine (abstract)
19. Value of acute vasodilators studies in management of primary pulmonary hypertension (abstract)
20. Nifedipine treatment for pulmonary hypertension in a patient with systemic sclerosis
21. Sustained beneficial effect of nifedipine in primary pulmonary hypertension
22. Cardiovascular effects of diltiazem in healthy volunteers at rest, supine and erect, and during physical and mental stress
23. Hemodynamic and gas exchange effects of intravenous diltiazem in patients with pulmonary hypertension
24. Slow‐channel blockers in heart failure: a plea for cautious optimism
25. Acute hemodynamic responses to sublingual nifedipine: dependence on left ventricular function
26. Comparison of acute haemodynamic effects of nifedipine and isosorbide dinitrate in patients with heart failure following acute myocardial infarction
27. Afterload reduction with nifedipine in aortic insufficiency
28. The treatment of severe Raynaud's phenomenon with verapamil
29. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon
30. Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomenon
31. Raynaud's disease and nifedipine
32. Calcium‐channel blockers and Raynaud's disease (letter)
33. Diltiazem and Raynaud's syndrome
34. Calcium‐channel blockers in migraine
35. Verapamil prophylaxis of migraine
36. Interaction of verapamil with human platelet α‐adrenergic receptors
37. Effects of nifedipine (Adalat) on platelet function in vitro and in vivo
38. The effects of nifedipine, a calcium antagonist, on platelet function
39. Nifedipine for coronary artery spasm after revascularization (letter)
40. The first American clinical trial of nifedipine in cardioplegia: a report of the first 12‐month experience
41. Myocardial protection through cold cardioplegia with potassium or diltiazem
42. Verapamil in Duchenne's muscular dystrophy
43. Acute respiratory failure following intravenous verapamil in Duchenne's muscular dystrophy
44. Nifedipine in the treatment of achalasia
45. Nifedipine for relief of esophageal chest pain
46. Nifedipine for relief of esophageal chest pain
47. Nifedipine in the treatment of diffuse oesophageal spasm
48. Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric, and radionuclide evaluation
49. Combined effects of diflunisal and nifedipine on uterine contractility in dysmenorrhoeic patients
50. Inhibition of myometrial activity by calcium antagonists
51. Effects of nifedipine on oxytocin‐ and prostaglandin F2 alpha‐induced activity in the post‐partum uterus
52. Effects of nifedipine on spontaneous and methylergometrine‐induced activity postpartum
53. Effect of nifedipine on histamine reactivity in asthma
54. Nifedipine inhibits deep‐inspiration‐induced bronchoconstriction in asthmatics (letter)
55. A calcium antagonist, nifedipine, modifies exercise‐induced asthma
56. The effect of calcium antagonist, nifedipine, in exercise‐induced asthma
57. Nifedipine in the prevention of asthma induced by exercise and histamine
58. Effects of nifedipine on antigen‐induced bronchoconstriction
59. Inhibition of airway reactivity by nifedipine in patients with coronary artery disease
60. Calcium antagonist in exercise‐induced asthma
61. Sodium cromoglycate and verapamil alone and in combination in exercise‐induced asthma
62. Calcium antagonists in exercise‐induced asthma
63. Renal effects of acute calcium blockade with nifedipine in hypertensive patients receiving beta‐adrenoceptor blocking drugs
64. Effectiveness of verapamil in the treatment of a manic patient
65. Verapamil for depression
66. Potention of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors
67. Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug
68. Verapamil restoration of daunorubicin responsiveness in daunorubicin‐resistant Ehrlich ascites carcinoma
69. Effects of intravenous and oral verapamil upon pressor and adrenal steroidogenic responses in normal man
70. Does verapamil influence glucose‐induced insulin release in man
71. Verapamil therapy and blood glucose concentration
72. Calcium‐antagonistic effects on glucose response to glucagon in patients with noninsulin‐dependent diabetes mellitus and in normoglycemic subjects
73. Improvement of glucose tolerance by verapamil in patients with noninsulin‐dependent diabetes mellitus
74. Hypercalcemic and calcium‐antagonistic effects on insulin release and oral glucose tolerance in man
75. Effect of nifedipine on blood sugar, insulin and glucagon levels after an oral glucose load
76. Hyperglycaemic effect of nifedipine (letter)
77. Hyperglycaemic effect of nifedipine